MedTrace Logo

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

NCT05272813 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-07-18

No results posted yet for this study

Summary

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

Conditions

Interventions

DRUG

MS-553

MS-553

Sponsors & Collaborators

  • Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kai Zhang, MD · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2023-11-28
Completion
2023-11-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272813 on ClinicalTrials.gov